Investigational Distone Deacetylase Inhibitors (HDACi) in Myeloproliferative Neoplasms

Researchers from a recent study suggest that HDACi are clearly active in MPN and there is good preclinical rationale for this. Their combination with ruxolitinib in myelofibrosis is promising, but note that the long-term tolerability of these agents is an important concern.

Expert Opin Investig Drugs